GRCE
Grace Therapeutics, Inc.
NASDAQ: GRCE · HEALTHCARE · BIOTECHNOLOGY
$2.35
-3.77% today
Updated 2026-06-05
Market cap
$35.59M
P/E ratio
—
P/S ratio
197.75x
EPS (TTM)
$-0.31
Dividend yield
—
52W range
$2 – $5
Volume
0.8M
WallStSmart proprietary scores
27
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.8
Quality
B3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
2.4
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$5.89
+150.64%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-2.22M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-12.27M | $-57.39M | $-17.44M | $-13.63M | $-3.18M |
| EPS | — | — | — | — | $-0.31 |
| Free cash flow | $-17.23M | $-15.93M | $-12.36M | $-14.90M | $-2.22M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Grace Therapeutics, Inc. trades at $2.35. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 2.39, it sits in the grey zone.
Frequently asked questions
What is Grace Therapeutics, Inc.'s stock price?
Grace Therapeutics, Inc. (GRCE) trades at $2.35, on a P/S of 197.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Grace Therapeutics, Inc. overvalued?
Grace Therapeutics, Inc. carries a Smart Value Score of 27/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Grace Therapeutics, Inc. (GRCE)?
The 12-month analyst consensus target is $5.89, about 150.6% above the current $2.35. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Grace Therapeutics, Inc.'s Altman Z-Score is 2.39, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio197.75x
ROE-12.57%
Beta0.36
50D MA$3.15
200D MA$3.35
Shares out0.02B
Float0.01B
Short ratio—
Avg volume0.8M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—